The role of opioid receptors in modulating Alzheimer’s Disease

Parthasaradhireddy Tanguturi, John M. Streicher

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Alzheimer’s disease (AD) is a complex neurological disorder characterized by accumulation of amyloid plaques and neurofibrillary tangles. Long term investigation of AD pathogenesis suggests that β-site amyloid precursor protein [APP] cleaving enzyme 1 (BACE1) and γ-secretase enzymes promote the amyloidogenic pathway and produce toxic Aβ peptides that are predisposed to aggregate in the brain. Hence, the targeted inhibition of BACE1/γ-secretase expression and function is a promising approach for AD therapy. Several reports have suggested that the opioid family of G-protein coupled receptors modulate the etiology of AD progression. It has also been found that changes in the signaling pathways of opioid receptors increased the expression of BACE1 and γ-secretase, and is strongly correlated with abnormal production of Aβ and pathogenesis of AD. Thus, the opioid receptor family is a promising candidate for targeted drug development to treat AD. In this review, we outline the involvement and mechanisms of opioid receptor signaling modulation in Alzheimer’s Disease progression.

Original languageEnglish (US)
Article number1056402
JournalFrontiers in Pharmacology
StatePublished - 2023


  • Alzheimer’s disease
  • amyloid-β
  • neurodegenerative disorders
  • opioid receptors
  • β-secretase-1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The role of opioid receptors in modulating Alzheimer’s Disease'. Together they form a unique fingerprint.

Cite this